Here are five highlights:
1. Mr. Vandebroekas is replacing Wim Goemaere who will continue to support Bone Therapeutics as a non-executive director.
2. Mr. Vandebroekas comes into this role with more than 15 years of executive finance experience.
3. Prior to joining Bone Therapeutics, Mr. Vandebroekas served as director and CFO of Moteo Two Wheels Europe, a company focused on manufacturing two wheelers.
4. Mr. Vandebroekas has served as group CFO of Fluxys, a European gas infrastructure group. There he was responsible for the financing of large infrastructure investments using diverse forms of funding on capital markets.
5. Bone Therapeutics is a bone cell therapy company addressing urgent medical needs in orthopedic and bone diseases.
More articles on practice management:
Metro Health Hospital 1st to adopt Mazor X in Mich.: 3 takeaways
Dr. James Lubowitz leaves practice to pursue research: 5 insights
92% of employers confident they will continue sponsoring health benefits in 5 years: 5 insights
